Evommune

EVMNPhase 2

Evommune is a clinical-stage biotech focused on evolving immunology by developing innovative oral therapies for chronic inflammatory diseases with significant unmet need. The company is led by industry veterans and is advancing a pipeline of two primary candidates, EVO756 (targeting MRGPRX2) and EVO301 (targeting IL-18), across multiple indications. Recent milestones include positive Phase 2a data for EVO301 in atopic dermatitis and a $125 million private placement in early 2026 to fund ongoing clinical development.

Market Cap

$735.5M

EVMN · Stock Price

USD 23.33+3.10 (+15.32%)

Historical price data

AI Company Overview

Technology Platform

Focuses on targeting key drivers of chronic inflammation, specifically modulating mast cell, sensory neuron, and T-cell activity through novel oral mechanisms such as MRGPRX2 and IL-18 inhibition.

Pipeline Snapshot

6 drugs in pipeline

Drug	Indication	Stage
EVO756 + EVO756 + EVO756 + Placebo control	Atoptic Dermatitis	Phase 2
EVO756 + EVO756 + EVO756 + Placebo control	Chronic Spontaneous Urticaria	Phase 2
EVO301 + Placebo	Atopic Dermatitis (AD)	Phase 2
Oral EVO756	Chronic Inducible Urticaria	Phase 2
EVO101	Atopic Dermatitis Eczema	Phase 2

Opportunities

The vast, underserved market for chronic inflammatory diseases and the patient preference for convenient oral therapies over injectables present a major growth opportunity.

Success in lead indications could allow expansion into adjacent inflammatory conditions (e.g., other dermatologic, gastrointestinal, or neurologic diseases) leveraging the same core mechanisms.

Risk Factors

Key risks include clinical trial failures, intense competition from established injectable biologics and oral JAK inhibitors, regulatory hurdles, and the ongoing need for substantial capital to fund late-stage development and potential commercialization.

Competitive Landscape

Evommune competes in the crowded immunology space against large pharma and biotech companies. Its main differentiation is the novel oral targeting of upstream inflammatory pathways (MRGPRX2, IL-18), which may offer improved safety and convenience compared to broad immunosuppressants or injectable biologics.

Publications

Pipeline